The three new kits are the Marimastat caproKit, SAHA caproKit and GDP caproKit, respectively, and increase the number of commercially available caproKits to seven.
The company’s caproKits are based on the proprietary Capture Compound Mass Spectrometry (CCMS) technology, a novel and direct way to investigate small molecule – protein interactions resulting in a functional reduction of proteome complexity. Capture Compounds enable direct isolation and identification of proteins, including membrane proteins, out of complex biological samples.
The new and existing caproKits target different areas of research ranging from signal transduction (cAMP, cGMP, Stauro and the new GDP caproKit) to epigenetics (SAH and the new SAHA caproKit), and proteases (Marimastat caproKit). Additional caproKits for applications in these and other research areas are under development and will be released in the coming months.
Hubert Koster, CEO of caprotec bioanalytics, said: “Our new caproKits are innovative and effective tools for researchers in the field of proteomics needing a solution for targeted reduction of sample complexity. Our most recent scientific publications in Molecular and Cellular Proteomics and Toxicological Sciences provide powerful testimonials for the capabilities of our CCMS technology.”